FBLG READ THE FULL FBLG RESEARCH REPORT Business Update Phase 1/2 Trial in Diabetic Foot Ulcers to Initiate in 2Q25 ...

Cytora, a clinical stage company developing unique stem cell treatments based on human Oral Mucosa Stem Cells (hOMSCs), reported today successful results of a Phase 1/2a clinical trial for treating ...

Cytora's proprietary oral mucosa stem cells treatment holds potential to be a game changer in the field of stem cell therapy YOKNEAM, Israel, April 9, 2025 /PRNewswire/ -- Cytora, a clinical stage ...

Your feet work hard every day supporting your body, absorbing impact and adapting to different surfaces. But they often get ...

Diabetic foot screening intervals could be extended beyond 1 year for patients at very low risk for diabetic foot complications.

BiomX’s acquisition of Adaptive Phage Therapeutics is looking like a good bet now that one of the treatments from the deal ...

BX211 was safe and well-toleratedBX211 produced sustained and statistically significant1 Percent Area Reduction (PAR) of ulcer size (p = 0.046 at ...

Discover evidence-based strategies for healing diabetic wounds, from immediate care steps to advanced treatments, nutritional ...

The global wound evacuators market is on a steady growth trajectory, with its size estimated at USD 383.3 million in 2022, and projected to reach USD 593.6 million by 2032, expanding at a CAGR of 4.1% ...